Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of DS-1062a versus docetaxel in previously treated advanced or metastatic non-small cell lung cancer
NL-OMON52040Phase 3Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing DS-1062a with Docetaxel (2 arms). Primary endpoints: Progression-free survival assessed by blinded independent central review and Overall survival. Started Oct 2021; status: recruiting.
02
Drugs
datopotamab deruxtecandocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON52040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52040.